Linio Biotech Ltd

What Linio Biotech Ltd does

Linio Biotech Ltd is a Finnish biotechnology company developing and commercializing Tience®, a first-of-its-kind, cell-free tissue product derived from human adipose tissue. Founded in 2017 by Professor Timo Ylikomi and Riina Uusmies based on adipose tissue research initiated at Tampere University in 2005, the company is headquartered in Helsinki with manufacturing operations at a Fimea-licensed tissue establishment (TE4008) in Tampere. Tience® uses bioactive substances from processed adipose tissue to activate the body's own regenerative mechanisms, delivering long-lasting improvements in skin condition, structure, and elasticity for aesthetic and therapeutic indications including volume restoration, scar treatment, post-surgical regeneration, and skin quality improvement.

The underlying platform combines proprietary cell biology with modern biomaterials and is protected by a new EPO patent granted in 2025, with five additional patent applications filed. Manufacturing occurs in EU GMP Class A/C clean rooms under end-to-end vertically integrated controls from donor evaluation through international distribution. An investigational hybrid injectable leveraging Tience® technology is in development with an initial focus on volume restoration, designed to combine immediate lifting effect with subsequent endogenous soft-tissue formation.

Linio Biotech generates revenue through direct sales of Tience® to healthcare clinics. The product is commercially used by approximately 40 leading clinics in Finland and Sweden, with Sweden launched in 2025 following the initial Finland launch in 2023. Nearly 2,000 treated patients have generated real-world post-market data supporting regulatory pathways and physician adoption. The company has raised over €10 million to date through equity and public grants, including a €4.2 million round in November 2023, and operates with a lean 11-50 employee structure targeting the $23.8 billion global aesthetic injectables market, where regenerative and biologically active solutions are growing at approximately 20% annually.

Name

Linio Biotech Ltd

Legal name

Linio Biotech Ltd

Website

https://linio-biotech.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Linio Biotech Ltd is a Finnish biotechnology company developing Tience®, a proprietary cell-free adipose tissue-derived injectable for skin regeneration. It serves aesthetic and dermatology clinics in Finland and Sweden through direct sales of its licensed tissue establishment products.

Ownership category

akta.pro rank

Product category

Regenerative Aesthetics Tissue Products

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

akta.pro secondary industries

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), First Aid & Wound Care (HLAIADAM)

Keywords

• Regenerative aesthetics
• Adipose tissue technology
• Cell-free injectables
• Tissue regeneration products
• Biologic dermatology solutions

Headquarters

HQ city

Helsinki

HQ country

Finland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales

Revenue model

1. Tience® Product Sales: Commercial sales of Tience® injectable tissue product to healthcare clinics in Finland and Sweden. The product is used by approximately 40 leading healthcare clinics for skin repair, regeneration, and aesthetic applications including volume restoration, scar treatments, and skin quality improvement.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Linio Biotech develops and commercially sells Tience®, a first-of-its-kind, cell-free injectable tissue product that harnesses the regenerative potential of human adipose tissue to improve skin functionality, structure, and elasticity. The product is sold to healthcare clinics in Finland and Sweden for volume restoration, scar treatments, post-surgical regeneration, soft-tissue defects, and skin quality improvement. An investigational hybrid injectable leveraging the same Tience platform is in development with initial focus on volume restoration.

Product overview

Linio Biotech is building a regenerative platform based on proprietary understanding of human adipose tissue and its role in skin and soft-tissue regeneration. The core offering is Tience®, a first-of-its-kind cell-free tissue product already used commercially in Finland and Sweden (~40 clinics). An investigational hybrid injectable leveraging Tience® technology is in development with initial focus on volume restoration. The platform technology enables multiple regenerative injectables across aesthetic and reconstructive indications including volume restoration, scar treatments, post-surgical regeneration, soft tissue defects, and skin quality improvement.

Differentiator

Problem solved

Functional benefit

Products and services

• Tience® First-of-its-kind, cell-free tissue product that improves skin functionality by harnessing the regenerative potential of human adipose tissue in a ready-to-use injectable format. Uses bioactive substances to naturally support skin repair and renewal processes, delivering long-lasting improvements in skin condition, structure, and elasticity. Indicated for volume restoration, scar treatments (including acne scars), post-surgical regeneration, soft-tissue defects, and skin quality improvement, sold to healthcare clinics and physicians.
• Investigational Hybrid Injectable (Tience®-based) Next-generation hybrid injectable combining an immediate lifting effect with subsequent support for endogenous soft-tissue formation, leveraging the proprietary Tience® adipose-derived platform technology. Designed for volume restoration with natural, long-lasting results aligned with patient and physician expectations; in development (pre-clinical) with planned progression toward MDR and FDA regulatory pathways.

Quantifiable outcome

• Tience® technology is clinically validated and used by ~40 leading healthcare clinics in Finland and Sweden
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Fimea (Finnish Medicines Agency)coreOthers · 1 January 2021Fimea granted Linio Biotech the tissue establishment license TE4008 in 2021, authorizing end-to-end tissue operations including procurement, processing, storage, and distribution of adipose tissue products.
• University of TurkucoreStrategic or Co-development PartnerAcademic research partnership in adipose tissue research and regenerative medicine. University collaboration supports Linio's foundation of world-leading knowledge in adipose-derived science.
• Tampere UniversitycoreStrategic or Co-development PartnerOrigin of Linio Biotech's founding story in 2005 when Professor Timo Ylikomi's pioneering research at Tampere University encouraged exploration of adipose tissue regenerative properties. Ongoing academic collaboration.
• Key Opinion Leaders (KOLs) Advisory BoardcoreStrategic or Co-development PartnerLinio Biotech works in close collaboration with leading international KOLs across medical aesthetics, dermatology, and regenerative medicine. Advisors contribute expertise in clinical study design, translational medicine, physician adoption, and regulatory strategy for global markets.
• Vita LaboratoriotminorChannel Partner/ Reseller/ DistributorHealthcare laboratory partner in Finland using and distributing Tience® products.
• Eira Medical Centre & HospitalminorChannel Partner/ Reseller/ DistributorHealthcare provider partner performing Tience® treatments in Finland.
• KC ClinicminorChannel Partner/ Reseller/ DistributorHealthcare clinic partner using Tience® technology for aesthetic treatments.
• KL SairaalaminorChannel Partner/ Reseller/ DistributorHealthcare provider partner in Finland utilizing Tience® products.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Galderma: Galderma is a global leader in dermatology and aesthetic injectables (Restylane, Sculptra) competing in the same $23.8B market Linio targets. As an established incumbent with regenerative and biostimulator franchises, it represents the most relevant large-scale comparison for Linio's commercial and expansion trajectory.
• Allergan Aesthetics (AbbVie): Allergan Aesthetics, an AbbVie division, dominates aesthetic injectables (Botox, Juvéderm, CoolSculpting) and is the category-defining incumbent. It serves as a benchmark for the scale and KOL relationships a regenerative aesthetics challenger like Linio must eventually compete with for global adoption.
• Merz Aesthetics: Merz Aesthetics markets Belotero, Radiesse, and Ultherapy across medical aesthetics and regenerative indications. Its biostimulator franchise (Radiesse) overlaps directly with Linio's positioning as natural, regenerative injectables.
• Integra LifeSciences: Integra LifeSciences is a publicly traded medical technology company with tissue regeneration and wound care franchises (Integra dermal matrix, AmnioExcel). It serves as a relevant comparable on the path from boutique regenerative product to scaled global tissue platform.

Direct peers

• Teoxane: Teoxane is a privately held Swiss developer of hyaluronic acid-based aesthetic injectables with a comparable geographic profile (European-headquartered, global expansion underway). It is a direct competitor in the medical aesthetics injectable category Linio targets.
• Organogenesis: Organogenesis is a leading regenerative medicine company (Apligraf, NuShield) focused on wound healing and skin regeneration using living cell and tissue technologies. It is one of the closest functional peers to Linio in delivering biological regenerative products for skin and wound indications.
• MiMedx: MiMedx commercializes placental tissue-based regenerative products (EpiFix, AmnioFix) for wound care and surgical recovery. It directly parallels Linio's strategy of monetizing biologically active tissue platforms for skin, soft-tissue, and wound healing use cases.
• Croma-Pharma: Croma-Pharma is an Austrian family-owned aesthetics company specializing in hyaluronic acid injectables, PRP, and regenerative threads. Its European mid-sized footprint, broad injectable portfolio, and global expansion make it one of the closest comparable competitors to Linio in scale and ambition.

Emerging players

• Vericel: Vericel develops autologous and allogeneic cell-based therapies (MACI, Epicel) for cartilage repair and severe burns — adjacent regenerative medicine applications with similar regulatory and manufacturing complexity. Useful comparable for capital intensity and pipeline economics.
• Suneva Medical: Suneva Medical commercializes regenerative aesthetics products including Bellafill (a collagen-based filler) and the RegenLab PRP system. As a privately held, aesthetics-focused regenerative player, it parallels Linio's commercial model and target customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/78853879/admin
• Instagraminstagram.com/liniobiotech

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Linio Biotech Ltd